12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FG-4592: Phase II data

The open-label Phase II Study 040 trial in 143 in patients with ESRD undergoing chronic hemodialysis whose hemoglobin levels were previously maintained on Epogen epoetin alpha plus IV iron supplementation showed that FG-4592 maintained hemoglobin levels for 19 weeks without IV iron supplementation vs. Epogen without IV iron supplementation. In the last...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >